Severe Community-Acquired Pneumonia

Critical Care Clinics

Volumn 29, Issue 3, 2013, Pages 563-601

  Sligl, Wendy I ^a   Marrie, Thomas J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Community acquired pneumonia; Intensive care; Lung; Pulmonary sepsis; Respiratory failure

Indexed keywords

ARGININE; AZITHROMYCIN; AZTREONAM; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; GLUCOCORTICOID; IMIPENEM; LEUKOCIDIN; LEVOFLOXACIN; LINEZOLID; PNEUMOCOCCUS VACCINE; TETRACYCLINE DERIVATIVE; VANCOMYCIN; VIRULENCE FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; BACTERIAL LOAD; BACTERIAL VIRULENCE; CAUCASIAN; CHRONIC RESPIRATORY FAILURE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; COXIELLA BURNETII; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE RESPONSE; DYSPNEA; EMPYEMA; ETHNICITY; EXTRACORPOREAL OXYGENATION; FEVER; GENETIC POLYMORPHISM; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFLUENZA; INTENSIVE CARE UNIT; LUNG ABSCESS; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PATIENT SATISFACTION; PENICILLIN RESISTANCE; PNEUMONIA SEVERITY INDEX; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME; SMOKING CESSATION; SOCIOECONOMICS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX PAIN; TRACHEOSTOMY;

COMMUNITY-ACQUIRED PNEUMONIA; INTENSIVE CARE; LUNG; PULMONARY SEPSIS; RESPIRATORY FAILURE;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DRUG RESISTANCE, MICROBIAL; FEMALE; HOSPITAL MORTALITY; HUMANS; IMMUNOCOMPROMISED HOST; INTENSIVE CARE UNITS; MALE; MICROBIOLOGICAL TECHNIQUES; PNEUMOCOCCAL VACCINES; PNEUMONIA; RADIOGRAPHY, THORACIC; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 84879996414     PISSN: 07490704     EISSN: 15578232     Source Type: Journal    
DOI: 10.1016/j.ccc.2013.03.009     Document Type: Review

References (253)

1. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
2. Heron M., Hoyert D.L., Murphy S.L., et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009, 57:1-134.
3. Minino A.M., Murphy S.L., Xu J., et al. Deaths: final data for 2008. Natl Vital Stat Rep 2011, 59:1-126.
4. Average length of stay and days of care - Number and rate of discharges by first-listed diagnostic categories. Centers for Disease Control and Prevention, 2009. Available at: Accessed October 20, 2012. http://www.cdc.gov/nchs/fastats/pneumonia.htm.
5. Grossman R.F., Rotschafer J.C., Tan J.S. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005, 118(Suppl 7A):29S-38S.
6. Ewig S., Woodhead M., Torres A. Towards a sensible comprehension of severe community-acquired pneumonia. Intensive Care Med 2011, 37:214-223.
7. Aronsky D., Dean N.C. How should we make the admission decision in community-acquired pneumonia?. Med Clin North Am 2001, 85:1397-1411.
8. Niederman M.S., McCombs J.S., Unger A.N., et al. The cost of treating community-acquired pneumonia. Clin Ther 1998, 20:820-837.
9. Marston B.J., Plouffe J.F., File T.M., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-1718.
10. Almirall J., Bolibar I., Vidal J., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000, 15:757-763.
11. Ioachimescu O.C., Ioachimescu A.G., Iannini P.B. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. Int J Antimicrob Agents 2004, 24:485-490.
12. Lamy O., Van Melle G., Cornuz J., et al. Clinical management of immunocompetent hospitalized patients with community-acquired pneumonia. Eur J Intern Med 2004, 15:28-34.
13. Bratzler D.W., Ma A., Nsa W. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis 2008, 47(Suppl 3):S193-S201.
14. Capelastegui A., Espana P.P., Quintana J.M., et al. Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period. Arch Bronconeumol 2006, 42:283-289. [in Spanish].
15. Cilloniz C., Ewig S., Ferrer M., et al. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care 2011, 15:R209.
16. Sligl W.I., Eurich D.T., Marrie T.J., et al. Age still matters: prognosticating short- and long-term mortality for critically ill patients with pneumonia. Crit Care Med 2010, 38:2126-2132.
17. Woodhead M., Welch C.A., Harrison D.A., et al. Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care 2006, 10(Suppl 2):S1.
18. Diaz A., Barria P., Niederman M., et al. Etiology of community-acquired pneumonia in hospitalized patients in chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007, 131:779-787.
19. Rello J., Catalan M., Diaz E., et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002, 28:1030-1035.
20. Bodi M., Rodriguez A., Sole-Violan J., et al. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America guidelines on survival. Clin Infect Dis 2005, 41:1709-1716.
21. Angus D.C., Marrie T.J., Obrosky D.S., et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166:717-723.
22. Lee J.H., Ryu Y.J., Chun E.M., et al. Outcomes and prognostic factors for severe community-acquired pneumonia that requires mechanical ventilation. Korean J Intern Med 2007, 22:157-163.
23. Valencia M., Badia J.R., Cavalcanti M., et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007, 132:515-522.
24. Wilson P.A., Ferguson J. Severe community-acquired pneumonia: an Australian perspective. Intern Med J 2005, 35:699-705.
25. Sligl W.I., Eurich D.T., Marrie T.J., et al. Only severely limited, premorbid functional status is associated with short- and long-term mortality in patients with pneumonia who are critically ill: a prospective observational study. Chest 2011, 139:88-94.
26. Pascual F.E., Matthay M.A., Bacchetti P., et al. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000, 117:503-512.
27. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
28. Respiratory Disease in Canada: Canadian Institute for Health Information. Available at: Accessed October 30, 2012. http://https://secure.cihi.ca/estore/productSeries.htm%3Fpc%3DPCC33.
29. Dodek P.M., Norena M., Keenan S.P., et al. Intensive care unit admissions for community-acquired pneumonia are seasonal but are not associated with weather or reports of influenza-like illness in the community. JCrit Care 2011, 26:228-233.
30. Marrie T.J., Huang J.Q. Epidemiology of community-acquired pneumonia in Edmonton, Alberta: an emergency department-based study. Can Respir J 2005, 12:139-142.
31. Marrie T.J., Durant H., Williams J.C., et al. Exposure to parturient cats: a risk factor for acquisition of Q fever in Maritime Canada. JInfect Dis 1988, 158:101-108.
32. Albrich W.C., Madhi S.A., Adrian P.V., et al. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis 2012, 54:601-609.
33. Werno A.M., Anderson T.P., Murdoch D.R. Association between pneumococcal load and disease severity in adults with pneumonia. JMed Microbiol 2012, 61:1129-1135.
34. Waterer G., Rello J. Why should we measure bacterial load when treating community-acquired pneumonia?. Curr Opin Infect Dis 2012, 24:137-141.
35. Nimmo G.R. USA300 abroad: global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2012, 18:725-734.
36. Kreienbuehl L., Charbonney E., Eggimann P. Community-acquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports. Ann Intensive Care 2011, 1:52.
37. Hatchette T.F., Gupta R., Marrie T.J. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000, 31:1349-1356.
38. Kunimasa K., Yoshioka H., Iwasaku M., et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. Intern Med 2012, 51:431-434.
39. Sanford J.P. Legionnaires' disease: one person's perspective. Ann Intern Med 1979, 90:699-703.
40. Nora T., Lomma M., Gomez-Valero L., et al. Molecular mimicry: an important virulence strategy employed by Legionella pneumophila to subvert host functions. Future Microbiol 2009, 4:691-701.
41. Gavrilovskaya I., Gorbunova E., Matthys V., et al. The Role of the Endothelium in HPS Pathogenesis and Potential Therapeutic Approaches. Adv Virol 2012, 2012:467059.
42. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003: World Health Organization. Available at: Accessed December 17, 2012. http://www.who.int/csr/sars/country/table2004_04_21/en/index.html.
43. Gerlier D. Emerging zoonotic viruses: new lessons on receptor and entry mechanisms. Curr Opin Virol 2011, 1:27-34.
44. Gordon C.L., Holmes N.E., Grayson M.L., et al. Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin Vaccine Immunol 2012, 19:446-448.
45. Eisen D.P., Stubbs J., Spilsbury D., et al. Low mannose-binding lectin complement activation function is associated with predisposition to Legionnaires' disease. Clin Exp Immunol 2007, 149:97-102.
46. Sole-Violan J., Garcia-Laorden M.I., Marcos-Ramos J.A., et al. The Fcgamma receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit Care Med 2011, 39:1388-1393.
47. Bautista E., Chotpitayasunondh T., Gao Z., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. NEngl J Med 2010, 362:1708-1719.
48. Everitt A.R., Clare S., Pertel T., et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012, 484:519-523.
49. Wunderink R.G., Waterer G.W. Community-acquired pneumonia: pathophysiology and host factors with focus on possible new approaches to management of lower respiratory tract infections. Infect Dis Clin North Am 2004, 18:743-759. vii.
50. Mason C.M., Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005, 26:11-17.
51. Shemer-Avni Y., Lieberman D. Chlamydia pneumoniae-induced ciliostasis in ciliated bronchial epithelial cells. JInfect Dis 1995, 171:1274-1278.
52. Liang H., Jiang W., Han Q., et al. Ciliary ultrastructural abnormalities in Mycoplasma pneumoniae pneumonia in 22 pediatric patients. Eur J Pediatr 2012, 171:559-563.
53. Mitchell A.M., Mitchell T.J. Streptococcus pneumoniae: virulence factors and variation. Clin Microbiol Infect 2010, 16:411-418.
54. Bruggemann H., Cazalet C., Buchrieser C. Adaptation of Legionella pneumophila to the host environment: role of protein secretion, effectors and eukaryotic-like proteins. Curr Opin Microbiol 2006, 9:86-94.
55. Almirall J., Bolibar I., Balanzo X., et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999, 13:349-355.
56. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
57. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167:950-955.
58. Hermos J.A., Young M.M., Fonda J.R., et al. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis 2012, 54:33-42.
59. Knol W., van Marum R.J., Jansen P.A., et al. Antipsychotic drug use and risk of pneumonia in elderly people. JAm Geriatr Soc 2008, 56:661-666.
60. Trifiro G., Gambassi G., Sen E.F., et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010, 152:418-425. W139-440.
61. Almirall J., Bolibar I., Serra-Prat M., et al. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J 2010, 36:1080-1087.
62. Marrie T.J. Community-acquired pneumonia. Clin Infect Dis 1994, 18:501-513. [quiz: 514-5].
63. Cilloniz C., Ewig S., Polverino E., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011, 66:340-346.
64. Restrepo M.I., Mortensen E.M., Velez J.A., et al. Acomparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008, 133:610-617.
65. Marrie T.J., Shariatzadeh M.R. Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 2007, 86:103-111.
66. Martin-Loeches I., Lisboa T., Rodriguez A., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620.
67. Rodriguez A., Mendia A., Sirvent J.M., et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007, 35:1493-1498.
68. Hageman J.C., Uyeki T.M., Francis J.S., et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006, 12:894-899.
69. Centers for Disease Control and Prevention (CDC) Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007, 56:325-329.
70. Kallen A.J., Brunkard J., Moore Z., et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009, 53:358-365.
71. Arancibia F., Bauer T.T., Ewig S., et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002, 162:1849-1858.
72. Johansson N., Kalin M., Tiveljung-Lindell A., et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010, 50:202-209.
73. Shibli F., Chazan B., Nitzan O., et al. Etiology of community-acquired pneumonia in hospitalized patients in northern Israel. Isr Med Assoc J 2010, 12:477-482.
74. Appelbaum P.C., Bhamjee A., Scragg J.N., et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977, 2:995-997.
75. Hoban D.J., Doern G.V., Fluit A.C., et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl 2):S81-S93.
76. Jacobs M.R., Good C.E., Windau A.R., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010, 54:2716-2719.
77. Moroney J.F., Fiore A.E., Harrison L.H., et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001, 33:797-805.
78. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with invitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
79. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
80. Turett G.S., Blum S., Fazal B.A., et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999, 29:321-327.
81. Klugman K.P. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002, 36:3s-8s.
82. Doern G.V., Richter S.S., Miller A., et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 2005, 41:139-148.
83. Daneman N., McGeer A., Green K., et al. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006, 43:432-438.
84. Feldman R.B., Rhew D.C., Wong J.Y., et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med 2003, 163:1718-1726.
85. Patel S.N., McGeer A., Melano R., et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 2011, 55:3703-3708.
86. Thornsberry C., Brown N.P., Draghi D.C., et al. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med 2008, 120:32-38.
87. Vanderkooi O.G., Low D.E., Green K., et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005, 40:1288-1297.
88. Barber M. Methicillin-resistant staphylococci. JClin Pathol 1961, 14:385-393.
89. Benner E.J., Kayser F.H. Growing clinical significance of methcillin-resistant Staphylococcus aureus. Lancet 1968, 2:741-744.
90. National Nosocomial Infections Surveillance System National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485.
91. Rubinstein E., Kollef M.H., Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(Suppl 5):S378-S385.
92. Li M., Diep B.A., Villaruz A.E., et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 2009, 106:5883-5888.
93. Labandeira-Rey M., Couzon F., Boisset S., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315:1130-1133.
94. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
95. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005, 40:100-107.
96. Hidron A.I., Low C.E., Honig E.G., et al. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009, 9:384-392.
97. Vardakas K.Z., Matthaiou D.K., Falagas M.E. Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia. Eur Respir J 2009, 34:1148-1158.
98. van der Flier M., van Dijk N.B., Fluit A.C., et al. Fatal pneumonia in an adolescent due to community-acquired methicillin-resistant Staphylococcus aureus positive for Panton-Valentine-leukocidin. Ned Tijdschr Geneeskd 2003, 147:1076-1079. [in Dutch].
99. Castaldo E.T., Yang E.Y. Severe sepsis attributable to community-associated methicillin-resistant Staphylococcus aureus: an emerging fatal problem. Am Surg 2007, 73:684-687. [discussion: 687-8].
100. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
101. Shrestha S.S., Swerdlow D.L., Borse R.H., et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis 2011, 52(Suppl 1):S75-S82.
102. Lum M.E., McMillan A.J., Brook C.W., et al. Impact of pandemic (H1N1) 2009 influenza on critical care capacity in Victoria. Med J Aust 2009, 191:502-506.
103. Kumar A., Zarychanski R., Pinto R., et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302:1872-1879.
104. Briand S., Fukuda K. Avian influenza A (H5N1) virus and 2 fundamental questions. JInfect Dis 2009, 199:1717-1719.
105. Stephenson I., Democratis J. Influenza: current threat from avian influenza. Br Med Bull 2005, 75-76:63-80.
106. Yuen K.Y., Chan P.K., Peiris M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998, 351:467-471.
107. Katz J.M., Lim W., Bridges C.B., et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. JInfect Dis 1999, 180:1763-1770.
108. Corman V., Eckerle I., Bleicker T., et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 2012, 17. pii:20285.
109. Danielsson N., On Behalf Of The Ecdc Internal Response Team, Catchpole M. Novel coronavirus associated with severe respiratory disease: case definition and public health measures. Euro Surveill 2012, 17. pii:20282.
110. Coronavirus Infections: World Health Organization. 2012. Available at: Accessed December 19, 2012. http://www.who.int/csr/disease/coronavirus_infections/en/index.html.
111. Bartlett J.G., Dowell S.F., Mandell L.A., et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347-382.
112. Metlay J.P., Kapoor W.N., Fine M.J. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997, 278:1440-1445.
113. Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982, 389:39-48.
114. Morley J.J., Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982, 389:406-418.
115. Vanderschueren S., Deeren D., Knockaert D.C., et al. Extremely elevated C-reactive protein. Eur J Intern Med 2006, 17:430-433.
116. Le Gall C., Desideri-Vaillant C., Nicolas X. Significations of extremely elevated C-reactive protein: about 91 cases in a French hospital center. Pathol Biol (Paris) 2011, 59:319-320. [in French].
117. Flanders S.A., Stein J., Shochat G., et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004, 116:529-535.
118. Holm A., Nexoe J., Bistrup L.A., et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007, 57:547-554.
119. Almirall J., Bolibar I., Toran P., et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004, 125:1335-1342.
120. Kruger S., Ewig S., Papassotiriou J., et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009, 10:65.
121. Simon L., Gauvin F., Amre D.K., et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217.
122. Boussekey N., Leroy O., Alfandari S., et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006, 32:469-472.
123. Christ-Crain M., Jaccard-Stolz D., Bingisser R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
124. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
125. Schuetz P., Christ-Crain M., Thomann R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
126. Masia M., Gutierrez F., Shum C., et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005, 128:2223-2229.
127. Muller F., Christ-Crain M., Bregenzer T., et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010, 138:121-129.
128. Pugh R., Grant C., Cooke R.P., et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2011, (10). CD007577.
129. Mayo J.R., Aldrich J., Muller N.L. Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 2003, 228:15-21.
130. Corbo J., Friedman B., Bijur P., et al. Limited usefulness of initial blood cultures in community acquired pneumonia. Emerg Med J 2004, 21:446-448.
131. Murray P.R., Washington J.A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975, 50:339-344.
132. Bartlett J.G., Finegold S.M. Bacteriology of expectorated sputum with quantitative culture and wash technique compared to transtracheal aspirates. Am Rev Respir Dis 1978, 117:1019-1027.
133. Jimenez P., Saldias F., Meneses M., et al. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia. Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993, 103:1023-1027.
134. Wimberley N., Faling L.J., Bartlett J.G. Afiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979, 119:337-343.
135. Sorde R., Falco V., Lowak M., et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011, 171:166-172.
136. Smith M.D., Derrington P., Evans R., et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. JClin Microbiol 2003, 41:2810-2813.
137. Helbig J.H., Uldum S.A., Bernander S., et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. JClin Microbiol 2003, 41:838-840.
138. Yu V.L., Plouffe J.F., Pastoris M.C., et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. JInfect Dis 2002, 186:127-128.
139. Fine M.J., Auble T.E., Yealy D.M., et al. Aprediction rule to identify low-risk patients with community-acquired pneumonia. NEngl J Med 1997, 336:243-250.
140. Lim W.S., van der Eerden M.M., Laing R., et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
141. Niederman M.S., Feldman C., Richards G.A. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006, 27:9-11.
142. Niederman M.S. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007, 131:1205-1215.
143. Kontou P., Kuti J.L., Nicolau D.P. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med 2009, 27:968-974.
144. Phua J., See K.C., Chan Y.H., et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009, 64:598-603.
145. Chalmers J.D., Taylor J.K., Mandal P., et al. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis 2011, 53:503-511.
146. Liapikou A., Ferrer M., Polverino E., et al. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009, 48:377-385.
147. Charles P.G., Wolfe R., Whitby M., et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384.
148. Rello J., Rodriguez A., Lisboa T., et al. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med 2009, 37:456-462.
149. Knaus W.A., Draper E.A., Wagner D.P., et al. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
150. Le Gall J.R., Lemeshow S., Saulnier F. Anew Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
151. Lim W.S., Baudouin S.V., George R.C., et al. BTS guidelines for the management ofcommunity acquired pneumonia in adults: update 2009. Thorax 2009, 64(Suppl 3):iii1-iii55.
152. Park M., Markus P., Matesic D., et al. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006, 97:681-687.
153. Gadde J., Spence M., Wheeler B., et al. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993, 270:2456-2463.
154. Jost B.C., Wedner H.J., Bloomberg G.R. Elective penicillin skin testing in a pediatric outpatient setting. Ann Allergy Asthma Immunol 2006, 97:807-812.
155. Macy E., Schatz M., Lin C., et al. The falling rate of positive penicillin skin tests from 1995 to 2007. Perm J 2009, 13:12-18.
156. Atanaskovic-Markovic M., Gaeta F., Medjo B., et al. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008, 63:237-240.
157. Romano A., Viola M., Gueant-Rodriguez R.M., et al. Imipenem in patients with immediate hypersensitivity to penicillins. NEngl J Med 2006, 354:2835-2837.
158. Atanaskovic-Markovic M., Velickovic T.C., Gavrovic-Jankulovic M., et al. Immediate allergic reactions to cephalosporins and penicillins and their cross-reactivity in children. Pediatr Allergy Immunol 2005, 16:341-347.
159. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
160. Dumitrescu O., Boisset S., Badiou C., et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 2007, 51:1515-1519.
161. Dumitrescu O., Badiou C., Bes M., et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008, 14:384-388.
162. Bernardo K., Pakulat N., Fleer S., et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 2004, 48:546-555.
163. Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC andfailure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
164. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
165. van Hal S.J., Lodise T.P., Paterson D.L. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54:755-771.
166. FDA Drug Safety Communication: Increase risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections: U.S. Food and Drug Administration. 2010. Available at: Accessed December 18, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm#aihp.
167. Prasad P., Sun J., Danner R.L., et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709.
168. Fiore A.E., Fry A., Shay D., et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-24.
169. Kiatboonsri S., Kiatboonsri C., Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010, 50:620.
170. Nicholson K.G., Aoki F.Y., Osterhaus A.D., et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850.
171. Kaiser L., Wat C., Mills T., et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003, 163:1667-1672.
172. Jefferson T., Demicheli V., Rivetti D., et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006, 367:303-313.
173. Rodriguez A., Diaz E., Martin-Loeches I., et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. JAntimicrob Chemother 2011, 66:1140-1149.
174. Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. JAntimicrob Chemother 2011, 66:959-963.
175. Louie J.K., Yang S., Acosta M., et al. Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09. Clin Infect Dis 2012, 55:1198-1204.
176. Ling L.M., Chow A.L., Lye D.C., et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010, 50:963-969.
177. Zhang G., Xia Z., Liu Y., et al. Epidemiological and clinical features of 308 hospitalized patients with novel 2009 influenza A (H1N1) virus infection in China during the first pandemic wave. Intervirology 2011, 54:164-170.
178. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season: United States Centers for Disease Control and Prevention. Available at: Accessed December 18, 2012. http://www.cdc.gov/h1n1flu/recommendations.htm.
179. Taylor W.R., Thinh B.N., Anh G.T., et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 2008, 3:e3410.
180. Ariano R.E., Sitar D.S., Zelenitsky S.A., et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010, 182:357-363.
181. US Centers for Disease Control and Prevention. Prevention Strategies for Seasonal Influenza in Healthcare Settings. Accessed November 14, 2012. http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm.
182. Parnham M.J. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005, 18:125-131.
183. Giamarellos-Bourboulis E.J. Immunomodulatory therapies for sepsis: unexpected effects with macrolides. Int J Antimicrob Agents 2008, 32(Suppl 1):S39-S43.
184. Simpson J.L., Powell H., Boyle M.J., et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008, 177:148-155.
185. Albert R.K., Connett J., Bailey W.C., et al. Azithromycin for prevention of exacerbations of COPD. NEngl J Med 2011, 365:689-698.
186. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. JAntimicrob Chemother 2004, 54:21-28.
187. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444.
188. Restrepo M.I., Mortensen E.M., Waterer G.W., et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-159.
189. Ray W.A., Murray K.T., Hall K., et al. Azithromycin and the risk of cardiovascular death. NEngl J Med 2012, 366:1881-1890.
190. Baudel J.L., Tankovic J., Carrat F., et al. Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality?. Ther Clin Risk Manag 2009, 5:491-498.
191. Frei C.R., Attridge R.T., Mortensen E.M., et al. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther 2010, 32:293-299.
192. Asadi L., Sligl W.I., Eurich D.T., et al. Macrolide-Based Regimens and Mortality in Hospitalized Patients With Community-Acquired Pneumonia: a Systematic Review and Meta-analysis. Clin Infect Dis 2012, 55:371-380.
193. Mortensen E.M., Restrepo M., Anzueto A., et al. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004, 117:726-731.
194. Menendez R., Torres A., Zalacain R., et al. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005, 172:757-762.
195. McCabe C., Kirchner C., Zhang H., et al. Guideline-concordant therapy and reduced mortality and length of stay in adults with community-acquired pneumonia: playing by the rules. Arch Intern Med 2009, 169:1525-1531.
196. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248.
197. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
198. Hoang H., Sligl W.I., Eurich D.T., et al. Macrolide use in the treatment of critically ill patients with pneumonia; incidence, correlates, timing, and outcomes. Can J Infect Dis Med Microbiol 2012, 23(Suppl):B 24.
199. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164:637-644.
200. Mertz D., Koller M., Haller P., et al. Outcomes of early switching from intravenous to oral antibiotics on medical wards. JAntimicrob Chemother 2009, 64:188-199.
201. Oosterheert J.J., Bonten M.J., Schneider M.M., et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006, 333:1193.
202. van der Eerden M.M., de Graaff C.S., Vlaspolder F., et al. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia. Clin Ther 2004, 26:294-303.
203. Menendez R., Torres A., Zalacain R., et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004, 59:960-965.
204. Roson B., Carratala J., Fernandez-Sabe N., et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004, 164:502-508.
205. Arancibia F., Ewig S., Martinez J.A., et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000, 162:154-160.
206. Li J.Z., Winston L.G., Moore D.H., et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007, 120:783-790.
207. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:e18-e55.
208. Hayashi Y., Paterson D.L. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011, 52:1232-1240.
209. Avdic E., Cushinotto L.A., Hughes A.H., et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis 2012, 54:1581-1587.
210. Agarwal R., Aggarwal A.N., Gupta D., et al. Etiology and outcomes of pulmonary and extrapulmonary acute lung injury/ARDS in a respiratory ICU in North India. Chest 2006, 130:724-729.
211. Irish Critical Care Trials Group Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care 2008, 12:R30.
212. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. NEngl J Med 2000, 342:1301-1308.
213. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. NEngl J Med 2001, 345:1368-1377.
214. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. NEngl J Med 2008, 358:111-124.
215. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
216. Annane D., Bellissant E., Bollaert P.E., et al. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database Syst Rev 2004, (1). CD002243.
217. Sligl W.I., Milner D.A., Sundar S., et al. Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 2009, 49:93-101.
218. Confalonieri M., Urbino R., Potena A., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242-248.
219. Garcia-Vidal C., Calbo E., Pascual V., et al. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007, 30:951-956.
220. Snijders D., Daniels J.M., de Graaff C.S., et al. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 2010, 181:975-982.
221. Meijvis S.C., Hardeman H., Remmelts H.H., et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377:2023-2030.
222. Meduri G.U., Bell W.A., Confalonieri M. Glucocorticoid treatment in community-acquired pneumonia without severe sepsis: no evidence of efficacy. Am J Respir Crit Care Med 2010, 181:880-882.
223. Peek G.J., Mugford M., Tiruvoipati R., et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009, 374:1351-1363.
224. Noah M.A., Peek G.J., Finney S.J., et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011, 306:1659-1668.
225. Centers for Disease Control and Prevention (CDC) Smoking-attributable mortality, years of potential life lost, and productivity losses-United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008, 57:1226-1228.
226. Stead L.F., Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev 2012, (10). CD008286.
227. Musher D.M., Manof S.B., Liss C., et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. JInfect Dis 2010, 201:516-524.
228. Manoff S.B., Liss C., Caulfield M.J., et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65> or= years. JInfect Dis 2010, 201:525-533.
229. Shapiro E.D., Berg A.T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. NEngl J Med 1991, 325:1453-1460.
230. Moberley S.A., Holden J., Tatham D.P., et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, (1). CD000422.
231. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59:1102-1106.
232. Centers for Disease Control and Prevention (CDC) Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819.
233. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012, 61:613-618.
234. Fine M.J., Smith M.A., Carson C.A., et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996, 275:134-141.
235. Cabre M., Serra-Prat M., Force L., et al. Functional status as a risk factor for mortality in very elderly patients with pneumonia. Med Clin (Barc) 2008, 131:167-170.
236. Mody L., Sun R., Bradley S.F. Assessment of pneumonia in older adults: effect of functional status. JAm Geriatr Soc 2006, 54:1062-1067.
237. Torres O.H., Munoz J., Ruiz D., et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. JAm Geriatr Soc 2004, 52:1603-1609.
238. Davis R.B., Iezzoni L.I., Phillips R.S., et al. Predicting in-hospital mortality. The importance of functional status information. Med Care 1995, 33:906-921.
239. Metersky M.L., Waterer G., Nsa W., et al. Predictors of in-hospital vs postdischarge mortality in pneumonia. Chest 2012, 142:476-481.
240. Aspa J., Rajas O., Rodriguez de Castro F., et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006, 27:1010-1019.
241. Menendez R., Torres A., Reyes S., et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012, 39:156-162.
242. Marshall J.C., Cook D.J., Christou N.V., et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995, 23:1638-1652.
243. Vincent J.L., de Mendonca A., Cantraine F., et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26:1793-1800.
244. Seneff M.G., Zimmerman J.E., Knaus W.A., et al. Predicting the duration of mechanical ventilation. The importance of disease and patient characteristics. Chest 1996, 110:469-479.
245. Scheinhorn D.J., Hassenpflug M.S., Votto J.J., et al. Post-ICU mechanical ventilation at 23 long-term care hospitals: a multicenter outcomes study. Chest 2007, 131:85-93.
246. Bigatello L.M., Stelfox H.T., Berra L., et al. Outcome of patients undergoing prolonged mechanical ventilation after critical illness. Crit Care Med 2007, 35:2491-2497.
247. Viasus D., Garcia-Vidal C., Manresa F., et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. JInfect 2013, 66:27-33.
248. Corrales-Medina V.F., Suh K.N., Rose G., et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011, 8:e1001048.
249. Corrales-Medina V.F., Musher D.M., Wells G.A., et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012, 125:773-781.
250. Leroy O., Santre C., Beuscart C., et al. Afive-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995, 21:24-31.
251. Brown S.M., Jones J.P., Aronsky D., et al. Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia. Respirology 2012, 17:1207-1213.
252. Ewig S., de Roux A., Bauer T., et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004, 59:421-427.
253. Johnstone J., Marrie T.J., Eurich D.T., et al. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007, 167:1938-1943.